Predicting Outcomes of Indeterminate Bone Lesions on 18 F-DCFPyL PSMA PET/CT Scans in the Setting of High-Risk Primary or Recurrent Prostate Cancer
Journal of Nuclear Medicine · 2023-03 · 64 (3) · 395-401
DOI: 10.2967/jnumed.122.264334 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 20.10.2022. Verfasst von Tim E Phelps und 12 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; tim.phelps@nih.gov. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Bone Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Indeterminate bone lesions (IBLs) on prostate-specific membrane antigen (PSMA) PET/CT are common. This study aimed to define variables that predict whether such lesions are likely malignant or benign using features on PSMA PET/CT.
Methods
18F-DCFPyL PET/CT imaging was performed on 243 consecutive patients with high-risk primary or biochemically recurrent prostate cancer. IBLs identified on PSMA PET/CT could not definitively be interpreted as benign or malignant. Medical records of patients with IBLs were reviewed to determine the ultimate status of each lesion. IBLs were deemed malignant or benign on the basis of evidence of progression or stability at follow-up, respectively, or by biopsy results; IBLs were deemed equivocal when insufficient or unclear evidence existed. Post hoc patient, lesion, and scan variables accounting for clustered data were evaluated using Wilcoxon rank-sum and χ2 tests to determine features that favored benign or malignant interpretation.
Results
Overall, 98 IBLs within 267 bone lesions (36.7%) were identified in 48 of 243 patients (19.8%). Thirty-seven of 98 IBLs were deemed benign, and 42 were deemed malignant, of which 8 had histologic verification; 19 remained equivocal. Location and SUVmax categorical variables were predictive of IBL interpretation (P = 0.0201 and P = 0.0230, respectively). For IBLs with new interpretations, 34 of 37 (91.9%) considered benign showed an SUVmax of less than 5 or exhibited focal uptake without coexisting bone metastases; 37 of 42 (88.1%) deemed malignant demonstrated an SUVmax of at least 5 or were present with coexisting bone metastases. Logistic regression predicted IBLs with a high SUVmax (univariable: odds ratio [OR], 9.29 [P = 0.0016]; multivariable: OR, 13.87 [P = 0.0089]) or present with other bone metastases (univariable: OR, 9.87 [P = 0.0112]; multivariable: OR, 11.35 [P = 0.003]) to be malignant.
Conclusion
IBLs on PSMA PET/CT are concerning; however, characterizing their location, SUV, and additional scan findings can aid interpretation. IBLs displaying an SUVmax of at least 5 or present with other bone metastases favor malignancy. IBLs without accompanying bone metastases that exhibit an SUVmax of less than 5 and are observed only in atypical locations favor benign processes. These guidelines may assist in the interpretation of IBLs on PSMA PET/CT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; tim.phelps@nih.gov.
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
- Biometric Research Program, National Cancer Institute, National Institutes of Health, Rockville, Maryland.
- Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
- Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
- Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland.
Zitieren
APA
Phelps, T. E., Harmon, S. A., Mena, E., Lindenberg, L., Shih, J. H., Citrin, D. E., Pinto, P. A., Wood, B. J., Dahut, W. L., Gulley, J. L., Madan, R. A., Choyke, P. L., & Turkbey, B. (2023). Predicting Outcomes of Indeterminate Bone Lesions on 18 F-DCFPyL PSMA PET/CT Scans in the Setting of High-Risk Primary or Recurrent Prostate Cancer. Journal of Nuclear Medicine, 64(3), 395-401. https://doi.org/10.2967/jnumed.122.264334
Vancouver
Phelps TE, Harmon SA, Mena E, Lindenberg L, Shih JH, Citrin DE, et al. Predicting Outcomes of Indeterminate Bone Lesions on 18 F-DCFPyL PSMA PET/CT Scans in the Setting of High-Risk Primary or Recurrent Prostate Cancer. Journal of Nuclear Medicine. 2023;64(3):395-401. doi:10.2967/jnumed.122.264334
BibTeX
@article{Phelps2023,
author = {Phelps, Tim E and Harmon, Stephanie A and Mena, Esther and Lindenberg, Liza and Shih, Joanna H and Citrin, Deborah E and Pinto, Peter A and Wood, Bradford J and Dahut, William L and Gulley, James L and Madan, Ravi A and Choyke, Peter L and Turkbey, Baris},
title = {Predicting Outcomes of Indeterminate Bone Lesions on 18 F-DCFPyL PSMA PET/CT Scans in the Setting of High-Risk Primary or Recurrent Prostate Cancer},
journal = {Journal of Nuclear Medicine},
year = {2023},
volume = {64},
number = {3},
pages = {395--401},
doi = {10.2967/jnumed.122.264334}
}
EUVIMED